Title:
USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER
Document Type and Number:
WIPO Patent Application WO/2022/242692
Kind Code:
A1
Abstract:
Provided is use of an antibody-drug conjugate targeting Her2 in combination with an immune checkpoint inhibitor such as PD-1 antibody or PD-L1 antibody, in the preparation of a medicine for treating patients with urothelial cancer, especially locally advanced or metastatic urothelial cancer. Compared to treatment with either of the two drugs alone, treatment with both in combination has a marked synergistic effect and significant therapeutic effect. In addition, the combination treatment had good efficacy for patients with low HER2 IHC expression (1+).
Inventors:
FANG JIANMIN (CN)
JIANG JING (CN)
LI SHENJUN (CN)
SU XIAOHONG (CN)
JIANG JING (CN)
LI SHENJUN (CN)
SU XIAOHONG (CN)
Application Number:
PCT/CN2022/093631
Publication Date:
November 24, 2022
Filing Date:
May 18, 2022
Export Citation:
Assignee:
REMEGEN CO LTD (CN)
International Classes:
A61K39/395; A61K35/00; A61K45/00; A61K47/20; A61P43/00
Domestic Patent References:
| WO2020042941A1 | 2020-03-05 | |||
| WO2021086981A1 | 2021-05-06 |
Foreign References:
| CN110049779A | 2019-07-23 | |||
| US20210101888A1 | 2021-04-08 | |||
| US20210093730A1 | 2021-04-01 | |||
| US20210101982A1 | 2021-04-08 | |||
| US20180110772A1 | 2018-04-26 | |||
| US20180271996A1 | 2018-09-27 |
Other References:
LATTANZI MICHAEL, ROSENBERG JONATHAN E.: "The emerging role of antibody-drug conjugates in urothelial carcinoma", EXPERT REVIEW OF ANTICANCER THERAPY, EXPERT REVIEWS LTD., GB, vol. 20, no. 7, 31 July 2020 (2020-07-31), GB , pages 551 - 561, XP009541182, ISSN: 1473-7140, DOI: 10.1080/14737140.2020.1782201
SHENG XINAN, YAN XIEQIAO, WANG LIN, SHI YANXIA, YAO XIN, LUO HONG, SHI BENKANG, LIU JIYAN, HE ZHISONG, YU GUOHUA, YING JIANMING, H: "Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 27, no. 1, 1 January 2021 (2021-01-01), US, pages 43 - 51, XP093006324, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-20-2488
GUO LEI, CHENG SI-QI;LI JIA-MIN: "Global approved new drugs in 2019: reported and prospect", JOURNAL OF MULTIDISCIPLINARY CANCER MANAGEMENT(ELECTRONIC VERSION), vol. 6, no. 1, 30 January 2020 (2020-01-30), pages 70 - 79, XP093006321, DOI: 10.12151/JMCM.2020.01-09
SHENG XINAN, YAN XIEQIAO, WANG LIN, SHI YANXIA, YAO XIN, LUO HONG, SHI BENKANG, LIU JIYAN, HE ZHISONG, YU GUOHUA, YING JIANMING, H: "Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 27, no. 1, 1 January 2021 (2021-01-01), US, pages 43 - 51, XP093006324, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-20-2488
GUO LEI, CHENG SI-QI;LI JIA-MIN: "Global approved new drugs in 2019: reported and prospect", JOURNAL OF MULTIDISCIPLINARY CANCER MANAGEMENT(ELECTRONIC VERSION), vol. 6, no. 1, 30 January 2020 (2020-01-30), pages 70 - 79, XP093006321, DOI: 10.12151/JMCM.2020.01-09
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF: